The Indian Council of Medical Research (ICMR) has transferred the rights for three homegrown medical technologies to Indian drugmakers Emcure Pharmaceuticals and Biological E for commercial development. The move is aimed at helping promising public-sector research reach the market faster and support more affordable healthcare solutions.
Under the agreement, Emcure will take forward a cervical cancer drug candidate, while Biological E will develop two vaccine technologies. By handing these technologies to established pharmaceutical companies, ICMR is seeking to bridge the gap between laboratory innovation and large-scale production.
The development highlights a broader push to convert indigenous medical research into products that can be manufactured and distributed widely. It also reflects growing collaboration between public research institutions and private industry to strengthen India’s healthcare innovation pipeline.
If successfully developed, these technologies could add to locally created treatment and prevention options and reinforce the role of Indian companies in bringing research-backed healthcare products to patients. The handover marks another step in turning domestic scientific work into commercially viable medical solutions.
